Hyloris Pharmaceuticals has named Dietmar Aichhorn to become its chief operating officer from the start of October, marking the latest step in a journey for the Belgian value-added medicines specialist that has already this year completed a successful initial public offering following a funding round at the start of 2020. The firm has also received the first European approvals for one of its key products, the Maxigesic IV (paracetamol/ibuprofen) pain treatment.
Aichhorn joins Hyloris from Polpharma Biologics – where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing scientific affairs – and has also previously served at
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?